A major study of nearly 4 million children offers reassurance that benzodiazepines and Z-hypnotics during pregnancy don’t increase psychiatric risks when family factors are considered.
A massive South Korean study has found no significant link between prenatal exposure to common sedatives and psychiatric disorders in children. The research, published in BMJ, analysed 3,809,949 children born between 2010 and 2022.
The findings challenge earlier concerns about these widely prescribed medications during pregnancy.
What the Numbers Show
The study tracked 94,482 children — about 2.5% of all births — who were exposed to benzodiazepines or Z-hypnotics in the womb. These drugs are commonly prescribed for anxiety and insomnia, affecting roughly one in five pregnancies.
Initial analysis suggested higher psychiatric risks in exposed children. But when researchers controlled for family factors using sibling comparisons, the association vanished. The hazard ratio dropped to 0.99 — essentially no difference at all.
The sibling-controlled analysis is central. It accounts for shared genetic and environmental factors that might skew results.
Specific Conditions Examined
Researchers examined 12 specific psychiatric conditions. ADHD, autism, schizophrenia, and intellectual disability all showed no increased risk after proper analysis.
The study followed children until 2023, recording 10,060 psychiatric events in the exposed group versus 311,997 in unexposed children.
Some modest risk elevations persisted in specific subgroups. Exposure during the second half of pregnancy showed slightly higher risks — but the confidence intervals included no effect.
Contrasting Evidence
Not all research agrees. A Swedish study found prenatal exposure to these drugs was associated with increased neurodevelopmental risks. That research suggested dose-response patterns and urged cautious prescribing.
The conflicting findings highlight the complexity of studying drug effects during pregnancy. Different populations, methods, and definitions can yield different results.
Current Prescribing Guidance
NHS guidelines already recommend non-drug approaches for anxiety and insomnia during pregnancy as first-line treatment. Benzodiazepines and Z-drugs should only be used when benefits clearly outweigh risks.
The medications cross the placental barrier and could theoretically affect developing brains. But this new evidence suggests those concerns may be overblown.
Source: @bmj_latest
Key Takeaways
- Nearly 4 million children studied with no overall psychiatric risk from prenatal sedative exposure
- Sibling-controlled analysis eliminates confounding family factors that skewed earlier research
- Some modest risks may persist for specific timing of exposure during pregnancy
What This Means for Kent Residents
Kent women currently taking benzodiazepines or Z-hypnotics during pregnancy can discuss these reassuring findings with their GPs or midwives. NHS Kent and Medway ICB maternity services follow national guidelines recommending individual risk assessments for each case. Expectant mothers should still explore non-drug alternatives like cognitive behavioural therapy first, but this research provides valuable reassurance for those who need medication — contact your local midwifery team for personalised advice on managing anxiety or sleep problems during pregnancy.